Cargando…
BRAF V600 mutations and pathological features in Japanese melanoma patients
Ultraviolet radiation is a risk factor for BRAF V600 mutations frequently found in melanomas that cause constitutive BRAF activation. Primary sites of melanoma and the frequency of BRAF mutations might differ between races. Melanoma is rare in Japan (1500–2000 cases/year compared with 132 000/year w...
Autores principales: | Yamazaki, Naoya, Tanaka, Ryota, Tsutsumida, Arata, Namikawa, Kenjiro, Eguchi, Hironobu, Omata, Wataru, Oashi, Kohei, Ogawa, Toru, Hayashi, Amiko, Nakamura, Noriyuki, Tsuta, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276568/ https://www.ncbi.nlm.nih.gov/pubmed/25051202 http://dx.doi.org/10.1097/CMR.0000000000000091 |
Ejemplares similares
-
Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2018) -
A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol)
por: Oashi, Kohei, et al.
Publicado: (2020) -
Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses
por: Omata, W., et al.
Publicado: (2017) -
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
por: Nakamura, Yoshio, et al.
Publicado: (2016) -
Systemic therapy for Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study)
por: Namikawa, Kenjiro, et al.
Publicado: (2023)